Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 7.77
-0.12 (-1.52%)
Sep 2, 2026, 5:29 PM CET
Egetis Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 66 | 62.4 | 46.1 | 57.6 | 22.6 | 38.2 |
| 66 | 62.4 | 46.1 | 57.6 | 22.6 | 38.2 | |
Revenue Growth | 39.53% | 35.36% | -19.96% | 154.87% | -40.84% | -6.05% |
Cost of Revenue | 55 | 50 | 11.6 | 11 | 142.6 | 96.6 |
Gross Profit | 11 | 12.4 | 34.5 | 46.6 | -120 | -58.4 |
Selling, General & Admin | 254.1 | 201 | 215.3 | 172.8 | 74.3 | 44.6 |
Research & Development | 156.1 | 158.3 | 146.2 | 194 | - | - |
Other Operating Expenses | -10.1 | -16.9 | -5.2 | -8.9 | - | -0.3 |
Operating Expenses | 400.1 | 342.4 | 356.3 | 357.9 | 77 | 46.8 |
Operating Income | -389.1 | -330 | -321.8 | -311.3 | -197 | -105.2 |
Interest Expense | -10.1 | -14.4 | -17.6 | -4.2 | -0.1 | -0.2 |
Interest & Investment Income | 5.5 | 5.2 | 6.9 | 4.9 | 0.9 | 0.1 |
Currency Exchange Gain (Loss) | -10.3 | -10.3 | -6.3 | -13.4 | 2.4 | 0.6 |
Other Non Operating Income (Expenses) | -1 | 7.4 | -4.5 | -2.8 | - | 0.2 |
Pretax Income | -405 | -342.1 | -343.3 | -326.8 | -193.8 | -104.5 |
Income Tax Expense | 0.4 | 0.4 | 0.3 | 0.1 | - | - |
Net Income | -405.4 | -342.5 | -343.6 | -326.9 | -193.8 | -104.5 |
Net Income to Common | -405.4 | -342.5 | -343.6 | -326.9 | -193.8 | -104.5 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 400 | 368 | 307 | 257 | 194 | 180 |
Shares Outstanding (Diluted) | 400 | 373 | 311 | 260 | 194 | 180 |
Shares Change | 17.59% | 20.10% | 19.57% | 33.86% | 7.97% | 166.96% |
EPS (Basic) | -1.01 | -0.93 | -1.12 | -1.27 | -1.00 | -0.58 |
EPS (Diluted) | -1.01 | -0.93 | -1.12 | -1.30 | -1.00 | -0.60 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -299.6 | -267 | -227.9 | -278.4 | -173.5 | -130.3 |
Free Cash Flow Per Share | -0.75 | -0.71 | -0.73 | -1.07 | -0.89 | -0.72 |
Gross Margin | 16.67% | 19.87% | 74.84% | 80.90% | - | -152.88% |
Operating Margin | -589.55% | -528.85% | -698.05% | -540.45% | -871.68% | -275.39% |
Profit Margin | -614.24% | -548.88% | -745.34% | -567.53% | -857.52% | -273.56% |
Free Cash Flow Margin | -453.94% | -427.89% | -494.36% | -483.33% | -767.70% | -341.10% |
EBITDA | -381 | -328.6 | -320.7 | -310.2 | -195.8 | -104 |
EBITDA Margin | - | - | - | - | - | -272.25% |
D&A For EBITDA | 8.1 | 1.4 | 1.1 | 1.1 | 1.2 | 1.2 |
EBIT | -389.1 | -330 | -321.8 | -311.3 | -197 | -105.2 |
EBIT Margin | - | - | - | - | - | -275.39% |
Revenue as Reported | - | - | - | - | 22.6 | 38.5 |